Dr. Évelyne Vinet receives the CRA’s Young Investigator Award - Dr. Évelyne Vinet receives the CRA’s Young Investigator Award - Research Institute of the McGill University Health Centre
Newsletter - Banner
Dr. Évelyne Vinet, a rheumatologist and an Assistant Professor in the Division of Rheumatology at McGill University’s Faculty of Medicine, has been selected as the 2018 recipient of the Canadian Rheumatology Association’s (CRA) Young Investigator Award. Dr. Vinet, who obtained her PhD from the Department of Epidemiology, Biostatistics and Occupational Health at McGill, focuses her research on reproductive issues in women with rheumatic diseases.
The CRA award recognizes a young Canadian Investigator who has contributed significant, original research in rheumatology. The candidate must be a CRA member in good standing and must be no more than seven years into becoming established as an Independent Investigator, who has performed outstanding, landmark, original research (clinical or basic science) in rheumatology as judged by peers and citations.
“I feel extremely privileged and honoured to be recognized by my peers for my research accomplishments,” says Dr. Vinet. “It is an important milestone in my career, which I believe I could not have reached without the staunch support of my mentor, Dr. Sasha Bernatsky, and those who have always encouraged me to strive for success.”
Dr. Vinet, who has been a researcher at the Research Institute of the McGill University Health Centre since 2014, has made substantial contributions to the field of reproductive issues in rheumatic diseases during the early stages of her career. Over the past few years, she has put together the world’s largest cohort of children born to women with systemic lupus erythematosus (SLE) to evaluate long-term outcomes of children born to mothers with SLE. More recently, she expanded her work to study important drug exposures during pregnancy in rheumatic diseases. Notably, she assessed the risk of serious infections in rheumatoid arthritis (RA) offspring exposed in utero to TNF inhibitors compared to unexposed RA offspring and children from the general population, using a large U.S. database.